Abstract: Lung cancer is one of the most common types of malignancy. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases. Epidermal growth factor receptor (EGFR) targeted therapy can significantly improve the prognosis of patients with advanced NSCLC. In this case, determining EGFR mutation status is critical in selecting an optimal treatment regimen for these patients. However, the acquisition of good-quality tumor tissues for genetic alteration analysis remains a challenge for patients who cannot bear surgery and biopsy. Therefore, noninvasive in vivo diagnosis of EGFR mutation status in NSCLC patients is critical for patient management. Positron emission tomography (PET) with specific probe targeted to EGFR has the potential to fulfill this requirement. This study provides a brief review of the value of PET with multiple tracers in predicting the status of EGFR mutation.